Yahoo Finance Eastwood Bio-Medical Canada Full Year 2023 Earnings: CA$0.008 loss per share (vs CA$0.002 loss in FY 2022)
Eastwood Bio-Medical Canada (CVE:EBM) Full Year 2023 Results
Key Financial Results
Revenue: CA$867.9k (down 33% from FY 2022).
Net loss: CA$546.6k (loss widened by 265% from FY 2022).
CA$0.008 loss per share (further deteriorated from CA$0.002 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eastwood Bio-Medical Canada's share price is broadly unchanged from a week ago.
Risk Analysis
It is worth noting though that we have found 5 warning signs for Eastwood Bio-Medical Canada (4 are a bit unpleasant!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
